6,12-dihydro-6-(2-oxoindolid-3-ene)-12-oxoindole<2,1-b>-quinazoline | 98931-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6,12-dihydro-6-(2-oxoindolid-3-ene)-12-oxoindole<2,1-b>-quinazoline
• 英文别名: (6E)-6-(2-oxo-1H-indol-3-ylidene)indolo[2,1-b]quinazolin-12-one
• CAS: 98931-18-1
• 化学式: C₂₃H₁₃N₃O₂
• 分子量: 363.375
• InChiKey: IVOGMCFNSCVEKF-FMQUCBEESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  28
• 可旋转键数：
  0
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-吲哚酮 、 色胺酮 在 三氟化硼乙醚 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以10%的产率得到6,12-dihydro-6-(2-oxoindolid-3-ene)-12-oxoindole<2,1-b>-quinazoline
  参考文献：
  名称：

  Structure determination of candidine, a violet indolic constituent from culture solutions of Candida lipolytica

  摘要：

  DOI：

  10.1016/s0040-4020(01)96610-4

文献信息

• AN EXTRACT FROM INDIGO NATURALIS AND A PROCESS FOR PREPARING THE SAME
  申请人：Galderma SA

  公开号：EP3482763A1

  公开（公告）日：2019-05-15

  The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.

  本发明涉及一种从一种或多种植物原料（如天然靛蓝）中制备提取物的工艺以及提取物本身。本发明还涉及一种包含该提取物的组合物，以及该组合物在医疗或美容方面的应用。
• Extract from indigo naturalis and a process for preparing the same
  申请人：Galderma S.A.

  公开号：US10251926B2

  公开（公告）日：2019-04-09

  The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.

  本发明涉及一种从一种或多种植物原料（如天然靛蓝）中制备提取物的工艺以及提取物本身。本发明还涉及一种包含该提取物的组合物，以及该组合物在医疗或美容方面的应用。
• Pharmaceutical composition comprising refined indigo naturalis extract and the use thereof
  申请人：Galderma S.A.

  公开号：US10232006B2

  公开（公告）日：2019-03-19

  A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

  本研究描述了一种精制的天然靛蓝提取物或靛蓝生产植物提取物，其活性成分总重量中至少含有 65%（重量比）的靛蓝素衍生物。 此外，还介绍了一种含有该精制提取物的药物组合物，以及使用该药物组合物治疗或缓解疾病或病症的方法。
• Pharmaceutical composition comprising refined Indigo naturalis extracts and the use thereof
  申请人：Galderma S.A.

  公开号：US10555985B2

  公开（公告）日：2020-02-11

  A refined Indigo Naturalis extract or Indigo-producing plant extract containing at least 65% (w/w) an indirubin derivative based on total weight of active ingredients is described. Also described are a pharmaceutical composition containing the refined extract, and the use of the pharmaceutical composition for treating or alleviating a disease or condition.

  本研究描述了一种精制的天然靛蓝提取物或靛蓝生产植物提取物，其活性成分总重量中至少含有 65%（重量比）的靛蓝素衍生物。此外，还介绍了一种含有该精制提取物的药物组合物，以及使用该药物组合物治疗或缓解疾病或病症的方法。
• Extract from Indigo Naturalis and a process for preparing the same
  申请人：Galderma S.A.

  公开号：US10695391B2

  公开（公告）日：2020-06-30

  The present invention relates to a process for preparing an extract from one or more botanical raw materials, such as Indigo Naturalis and the extract itself. The present invention also relates to a composition comprising the extract, as well as the use of composition in medical or cosmetic applications.

  本发明涉及一种从一种或多种植物原料（如天然靛蓝）中制备提取物的工艺以及提取物本身。本发明还涉及一种包含该提取物的组合物，以及该组合物在医疗或美容方面的应用。